Poseida Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Poseida Therapeutics has been acquired by Roche Holdings, completing a merger, delisting from Nasdaq, and becoming a wholly-owned subsidiary.
Roche Holdings, Inc. has agreed to acquire Poseida Therapeutics for $9.00 per share in cash at closing, plus a contingent value right (CVR) of up to $4.00 per share, potentially valuing the deal at $1.5 billion.
Poseida Therapeutics shared updates on its allogeneic CAR-T therapy pipeline, including clinical and preclinical data across hematologic malignancies, autoimmune diseases, and solid tumors, during a virtual R&D Day.
Poseida Therapeutics announced positive Q3 2024 financial results, highlighted by significant collaboration revenue and promising clinical trial updates for its allogeneic CAR-T therapies.
Poseida Therapeutics reported a 91% overall response rate in a Phase 1 trial for its P-BCMA-ALLO1 therapy in heavily pretreated multiple myeloma patients, using an optimized lymphodepletion regimen.
Poseida Therapeutics reported strong progress in its allogeneic cell therapy and genetic medicine programs, highlighted by key partnership advancements and upcoming clinical data readouts.
Poseida Therapeutics held its 2024 Annual Meeting of Stockholders, electing two Class I Directors and ratifying Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2024.
8-K: Poseida Therapeutics Announces First Quarter 2024 Results and Strategic Collaboration Expansion
Poseida Therapeutics reported a strong first quarter in 2024, highlighted by a new research collaboration with Astellas and promising clinical data updates.
Poseida Therapeutics and Astellas' subsidiary, Xyphos Biosciences, have entered a collaboration and license agreement to develop novel allogeneic cell therapies for solid tumors, potentially earning Poseida up to $600 million plus royalties.
Poseida Therapeutics is focusing on its non-viral genetic engineering platform and rare disease pipeline, showcasing advancements in gene editing and delivery technologies.
8-K: Poseida Therapeutics Announces Promising Phase 1 Data for Allogeneic CAR-T Therapies at AACR 2024
Poseida Therapeutics presented new data at the AACR 2024 meeting, highlighting the potential of their allogeneic CAR-T therapies, P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors, including the need for optimized lymphodepletion regimens.
Poseida Therapeutics reported positive clinical trial data for its allogeneic CAR-T therapies and provided financial results for 2023, highlighting a strong cash position and upcoming milestones.